Business Context and Reporting Period
Company: Wound Management Technologies, Inc. (WMT)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2010
Business Overview: WMT focuses on developing and marketing advanced wound care products, primarily through its subsidiary Wound Care Innovations, LLC (WCI), which holds exclusive rights to CellerateRX collagen products. The company has expanded its portfolio through acquisitions of BioPharma Management Technologies (Middle East distribution), Resorbable Orthopedic Products (patents), and eHealth (secure health data solutions).
Key Financial Metrics
| Metric | Three Months Ended June 30, 2010 | Six Months Ended June 30, 2010 |
|---|---|---|
| Total Revenue | $114,977 | $180,957 |
| Cost of Revenue | $28,419 | $48,814 |
| Gross Profit | $86,558 | $132,143 |
| Net Loss | $(663,006) | $(1,909,097) |
| Loss Per Share (Basic/Diluted) | $(0.02) | $(0.06) |
| Cash and Cash Equivalents | $22,029 (as of June 30, 2010) | N/A |
| Total Current Liabilities | $3,927,418 | N/A |
| Total Debt (Notes Payable & Debentures) | $2,990,715 (Current + Long Term) | N/A |
Liquidity: The company reported a working capital deficit, with current liabilities ($3.93M) significantly exceeding current assets ($0.71M). Cash on hand was $22,029 as of June 30, 2010.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 56% for the three months ended June 30, 2010, compared to the same period in 2009, driven by the addition of a sales and marketing team.
- Cost Reduction: Cost of revenue decreased 79% year-over-year due to the absence of advance royalty payments to the CellerateRX founder that were incurred in 2009.
- Expense Increase: General and Administrative (G&A) expenses surged 214% to $587,534, primarily due to increased consulting fees and wages for new sales personnel.
- Net Loss Expansion: Net loss increased 105% to $663,006 for the quarter, attributed to higher operating expenses and amortization of intangible assets acquired in late 2009.
- Debt Settlement: The company recognized a loss on debt settlement of $732,674 for the six-month period, largely due to converting debt to equity at a discount.
Outlook, Risks, and Contingencies
- Going Concern: The filing explicitly states that conditions raise substantial doubt about the company's ability to continue as a going concern. The company has a stockholders' deficiency and relies on proceeds from stock and note issuances to fund operations.
- Capital Needs: Management states a need to raise additional capital in fiscal year 2010 to fund the business plan. There is no assurance that capital raising efforts will be successful.
- Tax Liabilities: The company is delinquent on 2005-2006 payroll taxes. As of June 30, 2010, unpaid taxes totaled approximately $172,484, with penalties and interest of $193,970. A tax lien was filed in December 2009.
- Legal Proceedings: A Florida state court lawsuit regarding alleged nonpayment of brokerage commissions was settled in mediation during Q2 2010, with the company determined not liable for damages.
- Future Operations: The company is expanding distribution in Europe (via Biocure), the Southeast US (via KOMED), and Central America. First product deliveries in Europe are anticipated in Q4 2010.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $22,029 cash balance against the reported monthly burn rate and upcoming debt maturities.
- Debt Structure: Review the terms of the $2.18M in related-party notes and the $495,000 in convertible debentures, specifically regarding interest rates, maturity dates, and conversion discounts.
- IRS Status: Confirm the current status of the $366,454 total payroll tax liability (principal + penalties) and any progress on settlement with the IRS.
- Revenue Quality: Assess the sustainability of the 56% revenue increase and the impact of the new distribution agreements (KOMED, Biocure) on future cash flows.
- Related Party Transactions: Scrutinize the $1.5M note receivable from Private Access (acquired via VHGI) and the significant related-party debt holdings by affiliates of the CEO.